Locations
Cambridge, MA, USA · Dedham, MA, USA · Wellesley, MA, USA · Cambridge, MA, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Series B
founded in
2019
Qlaris Bio is a clinical stage biotechnology company dedicated to developing innovative first-in-class therapies for patients suffering from serious ophthalmic diseases. The company focuses on addressing unmet needs in ophthalmology, particularly through its lead asset, QLS-111, which targets episcleral venous pressure (EVP) to lower intraocular pressure (IOP) more effectively than existing therapies. QLS-111 is currently in development for conditions such as Normal Tension Glaucoma and Primary Open-Angle Glaucoma, positioning Qlaris Bio as a promising player in the ophthalmic therapeutics market.
Something looks off?